References
- ShawATYeapBYMino-KenudsonMClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKJ Clin Oncol200927264247425319667264
- SolomonBJMokTKimDWPROFILE 1014 InvestigatorsFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
- PetersSCamidgeDRShawATALEX Trial InvestigatorsAlectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancerN Engl J Med2017377982983828586279
- SoriaJCTanDSWChiariRFirst-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyLancet20173891007291792928126333
- CostaDBShawATOuSHClinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastasesJ Clin Oncol201533171881188825624436
- GainorJFDardaeiLYodaSMolecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancerCancer Discov20166101118113327432227
- ShawATGandhiLGadgeelSstudy investigatorsAlectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trialLancet Oncol201617223424226708155
- CrinòLAhnMJDe MarinisFMulticenter Phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2J Clin Oncol201634242866287327432917
- HuangWSLiuSZouDDiscovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinaseJ Med Chem201659104948496427144831
- ZhangSAnjumRSquillaceRThe potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical modelsClin Cancer Res201622225527553827780853
- CamidgeDRBazhenovaLSalgiaRSafety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC)J Clin Oncol201533 suppl; abstr 8062
- RosellRGettingerSNBazhenovaLA1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trialJ Thorac Oncol2016114 SupplS11427198273
- GettingerSNBazhenovaLALangerCJActivity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialLancet Oncol201617121683169627836716
- KimDWTiseoMAhnMJBrigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter Phase II trialJ Clin Oncol201735222490249828475456
- SolomonBJCappuzzoFFelipEIntracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014J Clin Oncol201634242858286527022118
- LangerCJHuangHHuangJPatient-reported outcomes and quality of life in ALTA: The randomized phase 2 study of brigatinib (BRG) in advanced ALK+ non–small cell lung cancer (NSCLC) [Internet]. [cited August 20, 2017]. Available from: http://meetinglibrary.asco.org/record/145768/abstractAccessed August 20, 2017
- BazhenovaLHodgsonJGLangerCJActivity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status [Internet]. [cited August 13, 2017]. Available from: http://meetinglibrary.asco.org/record/145774/abstractAccessed August 13, 2017
- CamidgeDRPaoWSequistLVAcquired resistance to TKIs in solid tumours: learning from lung cancerNat Rev Clin Oncol201411847348124981256
- UchiboriKInaseNArakiMBrigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancerNat Commun201781476828287083
- MokTSKimDWuYNakagawaKMekhailTFelipEOverall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in ALK+ Lung Cancer: Updated Results from PROFILE 1014Annals of Oncology201728suppl_5v605v64910.1093/annonc/mdx440